Amgen Inc. v. Sanofi
Decided May 18, 2023. Neil M. Gorsuch delivered the opinion of the Court.
Docket 21-757 · 598 U.S. 594 (2023) · Cited 23 times
Holding
Amgen’s two patent applications—purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism—fail to satisfy the Patent Act’s enablement clause, see 35 U. S. C. §112(a).
The Court’s statement of the holding, from the opinion’s syllabus. The syllabus is prepared by the Reporter of Decisions and is not part of the opinion of the Court. Read the official opinion for authority.
How the Justices voted
Decided 9–0.
Majority · 9
“Concurring” means agreeing with the outcome; any split shown is the Court’s judgment, not each Justice’s reasoning. The lineup is the syllabus’s disposition of who wrote and joined each opinion. Source: the opinion’s syllabus (supremecourt.gov).
Precedents cited
Supreme Court decisions this opinion relies on, ordered by how often it cites each. Cases in our collection link through; others are named.
- Holland Furniture Co. v. Perkins Glue Co. · 277 U.S. 245 (1928)
- Minerals Separation, Ltd. v. Hyde · 242 U.S. 261 (1916)
- Bonito Boats, Inc. v. Thunder Craft Boats, Inc. · 489 U.S. 141 (1989)
- Brenner v. Manson · 383 U.S. 519 (1966)
- Black v. Cutter Laboratories · 351 U.S. 292 (1956)
- Bilski v. Kappos · 561 U.S. 593 (2010)
- Continental Paper Bag Co. v. Eastern Paper Bag Co. · 210 U.S. 405 (1908)
- United States v. Dubilier Condenser Corp · 289 U.S. 178 (1933)
- Corona Cord Tire Co. v. Dovan Chemical Corp. · 276 U.S. 358 (1928)
Official text
Read the official opinion (PDF, supremecourt.gov)
Explore from here
Neil M. Gorsuch’s profile · All Supreme Court opinions · The Supreme Court
Source: Supreme Court of the United States, slip opinions (2023). Citation count from the Free Law Project’s CourtListener bulk data. Data last verified 2026-08-15. Informational only; verify against the primary source before relying. Not a consumer report (FCRA).